AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21519586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19348923 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized self-management education
Number of subjects: 95
Study 19348923 — intervention group
Group type: COMPARATOR
Intervention: Usual care with self-monitoring alone
Number of subjects: 95
Study 16766441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive hypnotherapy
Number of subjects: 20
Study 16766441 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 20
Study 14758577 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 7.5 mg/day
Number of subjects: 652
Study 14758577 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg/day
Number of subjects: 652
Study 14758577 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 652
Study 14758577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 11719736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 8 days
Number of subjects: 18
Study 11719736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg 4 times daily on day 8
Number of subjects: 18
Study 11719736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9407259 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (21 g.day-1)
Number of subjects: 18
Study 9407259 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 18
Study 29430142 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal laser sintering (MLS) technique
Number of subjects: 40
Study 29430142 — intervention group
Group type: COMPARATOR
Intervention: Lost-wax (LW) technique
Number of subjects: 40
Study 27346078 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn starch fiber at 90 g/day (multiple-serving study)
Number of subjects: 0
Study 27346078 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn starch fiber at 50 g/day (single-dose study)
Number of subjects: 0
Study 27346078 — intervention group
Group type: COMPARATOR
Intervention: Polydextrose at 90 g (positive control, multiple-serving study)
Number of subjects: 0
Study 27346078 — intervention group
Group type: COMPARATOR
Intervention: Polydextrose at 50 g (positive control, single-dose study)
Number of subjects: 0
Study 27346078 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn starch fiber at 30 g (single dose)
Number of subjects: 0
Study 27346078 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn starch fiber at 60 g (multiple servings)
Number of subjects: 0
Study 24969408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices (MAD)
Number of subjects: 32
Study 24969408 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 32
Study 22871048 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyherbal Unani formulation (topical application)
Number of subjects: 46
Study 22871048 — intervention group
Group type: COMPARATOR
Intervention: Sodium thiosulphate lotion (20%) (control group)
Number of subjects: 46
Study 19489496 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion on temperature-sensitive points, once each day for one course (7 days).
Number of subjects: 120
Study 19489496 — intervention group
Group type: COMPARATOR
Intervention: Traditional moxibustion at specific points (Jiaji, Ciliao, Zhibian, Huantiao, Weizhong, Yanglingquan, Kunlun), once each day for one course (7 days).
Number of subjects: 120
Study 19489496 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion on temperature-sensitive points (after 6 months follow-up).
Number of subjects: 120
Study 19489496 — intervention group
Group type: COMPARATOR
Intervention: Traditional moxibustion (after 6 months follow-up).
Number of subjects: 120
Study 17091134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B CrossAction (CA) toothbrush
Number of subjects: 60
Study 17091134 — intervention group
Group type: COMPARATOR
Intervention: Colgate Navigator (NA) toothbrush
Number of subjects: 60
Study 17091134 — intervention group
Group type: COMPARATOR
Intervention: Crest SpinBrush Pro (SBP) toothbrush
Number of subjects: 60
Study 15525254 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 92
Study 15525254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 11567957 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml applied four times daily
Number of subjects: 28
Study 11567957 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 50 microg/ml applied once daily
Number of subjects: 28
Study 11567957 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml applied once daily after 3 weeks without treatment
Number of subjects: 28
Study 11567957 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drop of latanoprost on day 50
Number of subjects: 28
Study 9671017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and mental stress testing
Number of subjects: 0
Study 9671017 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise alone
Number of subjects: 0
Study 9671017 — intervention group
Group type: COMPARATOR
Intervention: Mental stress alone
Number of subjects: 0
Study 7787215 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK receptor antagonist)
Number of subjects: 0
Study 7787215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham-feeding (MSF)
Number of subjects: 0
Study 7787215 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal
Number of subjects: 0
Study 7787215 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein infusion
Number of subjects: 0
Study 7787215 — intervention group
Group type: EXPERIMENTAL
Intervention: GRP infusion
Number of subjects: 0
Study 7787215 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of fat to standard meal
Number of subjects: 0
Study 7787215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric application of standard meal of pH 3.0
Number of subjects: 0
Study 7787215 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide pretreatment with standard meal of pH 6.5
Number of subjects: 0
Study 7787215 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide pretreatment
Number of subjects: 0
Study 7787215 — intervention group
Group type: COMPARATOR
Intervention: CCK antagonism
Number of subjects: 0
Study 3072365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 29
Study 3072365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31837056 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 14
Study 31837056 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 14
Study 31050652 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on the Yintang point
Number of subjects: 144
Study 31050652 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 144
Study 31050652 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 144
Study 28993390 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal clothing (socks, top and hat)
Number of subjects: 91
Study 28993390 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 91
Study 28993390 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal clothing
Number of subjects: 91
Study 25078053 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-step protocol using clomiphene citrate (CC) 50 mg/day for 5 days, then increased to 100 mg/day for 5 days if nonresponsive.
Number of subjects: 60
Study 25078053 — intervention group
Group type: COMPARATOR
Intervention: Traditional protocol using clomiphene citrate (CC) 100 mg/day for patients who failed the 50 mg/day treatment in the previous cycle.
Number of subjects: 60
Study 25078053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stair-step and traditional protocol)
Number of subjects: 60
Study 24336560 — intervention group
Group type: EXPERIMENTAL
Intervention: Call-in centre intervention
Number of subjects: 761
Study 21978235 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5% drops for 3 months (group 1)
Number of subjects: 27
Study 21978235 — intervention group
Group type: COMPARATOR
Intervention: Primary posterior capsulotomy combined with anterior vitrectomy (group 2)
Number of subjects: 27
Study 18434561 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tooth extraction
Number of subjects: 151
Study 18434561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth brushing
Number of subjects: 151
Study 16981473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone group
Number of subjects: 55
Study 16981473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 15632770 — intervention group
Group type: EXPERIMENTAL
Intervention: CR1 (one supervised exercise session per week over 52 weeks)
Number of subjects: 623
Study 15632770 — intervention group
Group type: EXPERIMENTAL
Intervention: CR2 (weekly supervised sessions for 26 weeks followed by one supervised session per month for the remaining 26 weeks)
Number of subjects: 623
Study 11719356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Cyclosporine A (CsA)
Number of subjects: 226
Study 9215828 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha 10 x 10(6) U/m2 subcutaneously on days 1 through 5 and high-dose IL-2 on days 3 through 8 without CDDP (arm A)
Number of subjects: 138
Study 9215828 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha 10 x 10(6) U/m2 subcutaneously on days 1 through 5 and high-dose IL-2 on days 3 through 8 with CDDP 100 mg/m2 on day 1 (arm B)
Number of subjects: 138
Study 8089640 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of oral terbinafine once daily for 2 weeks
Number of subjects: 64
Study 8089640 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of oral griseofulvin once daily for 2 weeks
Number of subjects: 64
Study 3301360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study 3301360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 20
Study 30414797 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI + TH (therapeutic hypothermia)
Number of subjects: 50
Study 30414797 — intervention group
Group type: COMPARATOR
Intervention: PPCI alone (Control)
Number of subjects: 50
Study 28976412 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitiram (generic drug)
Number of subjects: 37
Study 25639589 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenotherapy with hyperthermal water, rich in mineral salts for 12 days
Number of subjects: 137
Study 25639589 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% for 12 days
Number of subjects: 137
Study 23477959 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical-7 pulse CO-oximeter
Number of subjects: 12
Study 21815864 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (3 × 750 mg/day) alone
Number of subjects: 0
Study 21815864 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir plus pegylated interferon‐α‐2a (pegIFN‐α‐2a)
Number of subjects: 0
Study 21815864 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon‐α‐2a plus placebo
Number of subjects: 0
Study 19531904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 16
Study 19531904 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy men)
Number of subjects: 16
Study 16618947 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (RT)
Number of subjects: 3083
Study 16618947 — intervention group
Group type: COMPARATOR
Intervention: No postmastectomy radiotherapy (no RT)
Number of subjects: 3083
Study 15142150 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin nasal spray
Number of subjects: 64
Study 15142150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 11217910 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SALM/FP) via hydrofluoroalkane metered-dose inhaler (MDI) 50/100 microg, twice daily
Number of subjects: 497
Study 11217910 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SALM/FP) via Diskus inhaler 50/100 microg, twice daily
Number of subjects: 497
Study 11217910 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 microg via chlorofluorocarbon MDI, twice daily
Number of subjects: 497
Study 10205312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 30%
Number of subjects: 16
Study 10205312 — intervention group
Group type: COMPARATOR
Intervention: Intralipid 10%
Number of subjects: 16
Study 8019763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lithium (4 mEq kg‐1) in normal rats
Number of subjects: 0
Study 8019763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lithium (4 mEq kg‐1) in diabetic rats
Number of subjects: 0
Study 8019763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (0.5 g kg‐1) in lithium-treated diabetic rats
Number of subjects: 0
Study 8019763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (0.5 g kg‐1) in normal rats
Number of subjects: 0
Study 8019763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (0.5 g kg‐1) in both groups
Number of subjects: 0
Study 8019763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment in both normal and diabetic rats
Number of subjects: 0
Study 3217222 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% heart-rate reserve
Number of subjects: 24
Study 3217222 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% heart-rate reserve
Number of subjects: 24
Study 30804032 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed decision support strategies (Decision Aids - DAs)
Number of subjects: 1120
Study 30804032 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-directed decision support strategies (Decision Aids - DAs)
Number of subjects: 1120
Study 30804032 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons receiving a report detailing patients' goals and treatment preferences
Number of subjects: 1120
Study 30804032 — intervention group
Group type: COMPARATOR
Intervention: Surgeons not receiving a report detailing patients' goals and treatment preferences
Number of subjects: 1120
Study 27264198 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg TID, increased to 0.2 mg TID if hemodynamics stable)
Number of subjects: 40
Study 27264198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26742732 — intervention group
Group type: EXPERIMENTAL
Intervention: TomoTherapy
Number of subjects: 60
Study 26742732 — intervention group
Group type: COMPARATOR
Intervention: LINAC-IMRT
Number of subjects: 60
Study 23745526 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol aerosol solution (15μg/2mL) via nebulizer
Number of subjects: 20
Study 23745526 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol dry powder (50μg) via Diskus
Number of subjects: 20
Study 23745526 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 20
Study 21958534 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 20
Study 21958534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18588736 — intervention group
Group type: EXPERIMENTAL
Intervention: ganciclovir 10 mg/kg bodyweight for 21 days
Number of subjects: 23
Study 18588736 — intervention group
Group type: COMPARATOR
Intervention: Observation without therapy
Number of subjects: 23
Study 18588736 — intervention group
Group type: EXPERIMENTAL
Intervention: ganciclovir therapy
Number of subjects: 23
Study 17893906 — intervention group
Group type: EXPERIMENTAL
Intervention: Kattan-nomogram for prediction of indolent prostate cancer
Number of subjects: 825
Study 17893906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancers found at repeated screening after 4 years
Number of subjects: 825
Study 15136936 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification endoscopy for normal EGJ
Number of subjects: 88
Study 15136936 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification endoscopy for CLE
Number of subjects: 88
Study 15136936 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue staining
Number of subjects: 88
Study 15136936 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification endoscopy
Number of subjects: 88
Study 12430728 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer applied once daily for 3 weeks
Number of subjects: 19
Study 12430728 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer applied twice daily for 3 weeks
Number of subjects: 19
Study 12430728 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer (both dosages)
Number of subjects: 19
Study 12430728 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated regional area)
Number of subjects: 19
Study 9820354 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg oral ciprofloxacin
Number of subjects: 22
Study 9820354 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 22
Study 7697147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle block in addition to general anesthesia
Number of subjects: 40
Study 7697147 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (Control)
Number of subjects: 40
Study 2575975 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg tablet
Number of subjects: 12
Study 2575975 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg in solution
Number of subjects: 12
Study 2575975 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg intravenously
Number of subjects: 12
Study 2575975 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg tablet with food
Number of subjects: 12
Study 321067 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with BCG and autologous irradiated cells
Number of subjects: 15
Study 321067 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 15
Study 31483964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat 50 mg twice daily
Number of subjects: 52
Study 31483964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat 300 mg twice daily
Number of subjects: 52
Study 31483964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat (both dosages)
Number of subjects: 52
Study 27304428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (n=16)
Number of subjects: 33
Study 27304428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=17)
Number of subjects: 33
Study 26065433 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate
Number of subjects: 255
Study 26065433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 23843589 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial honey applied at the exit site
Number of subjects: 0
Study 23843589 — intervention group
Group type: COMPARATOR
Intervention: Standard topical application of mupirocin
Number of subjects: 0
Study 21734059 — intervention group
Group type: EXPERIMENTAL
Intervention: Total SFA
Number of subjects: 1032
Study 21734059 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cis PUFA
Number of subjects: 1032
Study 21734059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis (n-3) PUFA
Number of subjects: 1032
Study 21734059 — intervention group
Group type: EXPERIMENTAL
Intervention: PS ratio (PUFA:SFA)
Number of subjects: 1032
Study 21734059 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity-related metabolic factors adjustment
Number of subjects: 1032
Study 19848546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based breathing therapy (MBBT)
Number of subjects: 86
Study 19848546 — intervention group
Group type: COMPARATOR
Intervention: Support group
Number of subjects: 86
Study 16769401 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intubation (DI)
Number of subjects: 2
Study 16769401 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscope intubation (LI)
Number of subjects: 2
Study 15609886 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 48
Study 15609886 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C 500 mg/day
Number of subjects: 48
Study 15609886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11376310 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 5053
Study 11376310 — intervention group
Group type: COMPARATOR
Intervention: Older statins
Number of subjects: 5053
Study 11376310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 5053
Study 9369869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric quality of care indicators
Number of subjects: 557
Study 7926408 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of ivermectine (200 mcg/Kg)
Number of subjects: 55
Study 7926408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 3096764 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (1.5 mg/Kg/day) for 18 days
Number of subjects: 10
Study 3096764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31343789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment PTSD symptom networks
Number of subjects: 0
Study 31343789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean severity of symptoms at pretreatment
Number of subjects: 0
Study 29950456 — intervention group
Group type: EXPERIMENTAL
Intervention: BLISS (modified baby-led weaning)
Number of subjects: 206
Study 29950456 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 206
Study 27721228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg/d
Number of subjects: 73
Study 27721228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 24781374 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CAPS intervention
Number of subjects: 132
Study 21450587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive implementation programme for pharmacists
Number of subjects: 100